3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
267
Breast Neoplasms
256
Lung Neoplasms
130
Prostatic Neoplasms
113
Colorectal Neoplasms
106
Carcinoma, Non-Small-Cell Lung
101
Pancreatic Neoplasms
67
Carcinoma, Hepatocellular
53
Ovarian Neoplasms
50
Stomach Neoplasms
49
Multiple Myeloma
49
Hematologic Neoplasms
48
Urinary Bladder Neoplasms
47
Brain Neoplasms
45
Leukemia, Myeloid, Acute
42
Melanoma
41
Head and Neck Neoplasms
40
Esophageal Neoplasms
40
Disease
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Colonic Neoplasms
35
Rectal Neoplasms
34
Liver Neoplasms
34
Lymphoma
32
Neoplasm Metastasis
31
Leukemia, Lymphocytic, Chronic, B-Cell
30
Endometrial Neoplasms
30
Uterine Cervical Neoplasms
27
Thyroid Neoplasms
27
Kidney Neoplasms
27
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Unresectable Hepatocellular Carcinoma
×
90 days
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled